Warning: Undefined variable $zfal in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Deprecated: str_replace(): Passing null to parameter #3 ($subject) of type array|string is deprecated in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 530
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 531
 
English Wikipedia
Nephropedia Template TP (
Twit Text
DeepDyve
Pubget Overpricing |  
l�ll
Le PPAR gamma: une nouvelle cible pharmacologique contre la neovascularisation retinienne et choroidienne Bonne CJ Fr Ophtalmol 2005[Mar]; 28 (3): 326-30PPARg (peroxisome proliferator-activated receptor gamma) is a nuclear receptor that regulates the transcription of numerous genes involved in the differentiation, proliferation and apoptosis of various cell types. It was initially discovered in adipocytes as a differentiation agent, then was characterized in vascular endothelium and recently in choroidal and retinal endothelial cells. Agonists that bind to PPARgamma and stimulate its transcriptional activity are endogenous lipids such as lysophosphatidic acid and 15-d-PGJ2 as well as the synthetic pharmacological compounds, thiazolidinediones, used for treating type 2 diabetes. These ligands prevent choroidal and retinal neovascularization in several experimental animal models, notably through the inhibition of vascular endothelial growth factor (VEGF) receptor expression. Because of the high affinity and the low molecular weight of agonists, suitable for good bioavailability, PPARgamma could potentially be a novel pharmacological target of angiostatic agents, particularly useful to treat age-related macular degeneration and diabetic retinopathy.|Angiogenesis Inhibitors/pharmacology[MESH]|Animals[MESH]|Apoptosis[MESH]|Cells, Cultured[MESH]|Choroidal Neovascularization/*drug therapy[MESH]|Diabetic Retinopathy/*drug therapy[MESH]|Humans[MESH]|Ligands[MESH]|Macular Degeneration/*drug therapy[MESH]|Molecular Weight[MESH]|PPAR gamma/genetics/metabolism/pharmacology/*therapeutic use[MESH]|Polymorphism, Genetic[MESH]|Rats[MESH]|Receptors, Vascular Endothelial Growth Factor/antagonists & inhibitors[MESH]|Retinal Neovascularization/*drug therapy[MESH] |